Search results for: 'P9AC-01'

23 Jun 2016  |  North America  |  Market Research

Growth Opportunities in the US Point-of-care Testing Market

Digital Health Meets Point of Care—Emergence of Mobile Molecular Diagnostics

Infographics

×

The US point-of-care testing (POCT) study provides an extensive analysis for 13 segments: hematology, urinalysis, infectious disease, cardiac, HbA1c, glucose, fecal occult blood test/fecal immunochemical test (FOBT/FIT), coagulation PT/INR, coagulation APTT/ACT, cholesterol, pregnancy, drugs of abuse, and blood gas and electrolytes. Key trends and ...

After many years of basic research, regenerative medicine represents a remarkable foremost innovation in medical care. Comprising principles of stem cell technology and tissue engineering, also combining advanced biomaterials with small molecules and biologics, to replace or regenerate human tissues and organs and restore their functions, regenerat...

01 Jul 2016  |  Europe  |  Market Research

Western Europe Point-of-Care Testing (POCT) Market

Infographics

×

Point-of-care testing is an integral part of the IVD market that is rapidly evolving into a preferred testing mode in the EU region. POCT is a segment that presents growth opportunities for a cross-section of players, ranging from OEMs to data integrators to technology vendors. The stakeholders need to be abreast of the challenges posed by the indu...

27 Jun 2016  |  Global  |  Market Research

Market Assessment of MRI Equipment and its Emerging Clinical Applications

Infographics

×

The global MRI market is currently experiencing steady growth (mid-single digit growth rate). Although economic uncertainty and budgetary constraints have slowed down the market in certain countries, technological innovation and extended/new clinical applications of MRI due to their high importance in the imaging space have enabled it to overcome t...

12 Jul 2016  |  Asia Pacific  |  Market Research

Analysis of the APAC Health Information Exchange Market

 

Infographics

×

This research service analyzes the health information exchange (HIE) market in Asia-Pacific. Driven primarily by governments, the region is embarking on the next phase of healthcare IT transformation, investing in decentralizing patient information by enabling data exchange among established electronic medical record (EMR) and electronic health rec...

13 Sep 2016  |  North America  |  Market Research

US Next-generation Sequencing Services Market

$1,000 Genome Pricing and Throughput to Drive More and Larger Sequencing Projects

Infographics

×

The next-generation sequencing (NGS) services market includes all sequencing services conducted with next-generation or third-generation platforms that use newer technology than traditional capillary electrophoresis (CE) sequencing. Services include project scoping, NGS sample preparation tasks (i.e., library prep and target enrichment), and NGS-ba...

The US molecular diagnostics market is growing at 12.5% CAGR and is set to reach close to $6.5 billion by 2021. PCR, next-generation sequencing (NGS), microarray, and fluorescent in situ-hybridization (FISH) are the dominant technologies in this space with PCR holding more than 75% of the market. Roche, Cepheid, Qiagen, Abbott, and Thermo Fisher do...

21 Dec 2016  |  Africa  |  Market Research

African Pharmaceuticals Market, Forecast to 2020

Assessing Market Potential with a Focus on Kenya and Nigeria

Infographics

×

The pharmaceuticals market in Africa is expected to reach a business opportunity of $45 billion in 2020, propelled by a convergence of changing economic profiles, rapid urbanisation, increased healthcare spending and investment, and increasing incidence of chronic lifestyle diseases. The tropical climate of Africa makes the continent the largest re...

The treatment of rare diseases requires the use of specialized drugs. Patient populations for rare diseases are most often quite small, consequently the products treating them earn the designation orphan drugs. These drugs must undergo the research, development, and clinical trials that all drugs do, yet the investment into the development is great...